Memantine Mylan (Memantine Hydrochloride)

Memantine Mylan is an NMDA‑receptor antagonist used in the management of Alzheimer’s disease and related cognitive decline.

• Mild Alzheimer’s disease: modest improvement in memory and daily activities.
• Moderate Alzheimer’s disease: helps maintain cognitive function and daily living skills.
• Severe Alzheimer’s disease: may provide limited symptomatic benefit in cognition and behavior.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by glutamate over‑activation, thereby reducing excitotoxic neuronal damage that contributes to cognitive decline in Alzheimer’s disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: occasional disorientation.
• Fatigue: feeling unusually tired.
• Hypertension: mild increase in blood pressure.

Serious or Rare Side Effects

• Seizures: rare occurrence of convulsive episodes.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hallucinations or psychosis: visual or auditory disturbances.
• Stevens‑Johnson syndrome: severe skin reaction.
• Suicidal thoughts: emergent mood changes requiring immediate attention.

When prescribing Memantine Mylan, clinicians should consider several safety aspects.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• History of seizures: use with caution and observe for neurological changes.
• Concomitant NMDA antagonists: avoid combined use to prevent additive toxicity.
• Pregnancy: safety not established; weigh potential benefits against risks.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid)

• Other NMDA antagonists (e.g., amantadine, dextromethorphan): increased risk of neurotoxicity.
• Strong CYP450 inhibitors (e.g., ketoconazole, itraconazole): may raise memantine plasma concentrations.
• Strong CYP450 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.

Moderate Interactions (Monitor Closely)

• Diuretics: potential additive effect on blood pressure.
• Antihypertensive agents: enhanced hypotensive response.
• Central nervous system depressants (e.g., benzodiazepines): increased dizziness and sedation.